General information about company |
|||
|---|---|---|---|
| Scrip Code | 508869 | ||
| NSE Symbol | APOLLOHOSP | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE437A01024 | ||
| Name of company | APOLLO HOSPITALS ENTERPRISE LIMITED | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2024 | ||
| Date of end of financial year | 31-Mar-2025 | ||
| Date of board meeting when results were approved | 30-May-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 05-May-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | Fourth quarter | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Whether results are audited or unaudited for the quarter ended | Audited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited | ||
| Segment Reporting | Multi segment | ||
| Description of single segment | |||
| Start date and time of board meeting | 30-May-2025 12:15:00 | ||
| End date and time of board meeting | 30-May-2025 17:45:00 | ||
| Whether cash flow statement is applicable on company | Yes | ||
| Type of cash flow statement | Cash Flow Indirect | ||
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion | ||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 |
| B | Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 55922000000 | 217940000000 | |
| Other income | 611000000 | 2003000000 | |
| Total income | 56533000000 | 219943000000 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 6944000000 | 27544000000 |
| (b) | Purchases of stock-in-trade | 22436000000 | 85567000000 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -94000000 | -11000000 |
| (d) | Employee benefit expense | 7246000000 | 27692000000 |
| (e) | Finance costs | 1148000000 | 4585000000 |
| (f) | Depreciation, depletion and amortisation expense | 2110000000 | 7575000000 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 11693000000 | 46930000000 |
| Total other expenses | 11693000000 | 46930000000 | |
| Total expenses | 51483000000 | 199882000000 | |
| 3 | Total profit before exceptional items and tax | 5050000000 | 20061000000 |
| 4 | Exceptional items | 0 | 0 |
| 5 | Total profit before tax | 5050000000 | 20061000000 |
| 6 | Tax expense | ||
| 7 | Current tax | 1190000000 | 5263000000 |
| 8 | Deferred tax | -180000000 | 77000000 |
| 9 | Total tax expenses | 1010000000 | 5340000000 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | 0 |
| 11 | Net Profit Loss for the period from continuing operations | 4040000000 | 14721000000 |
| 12 | Profit (loss) from discontinued operations before tax | 0 | 0 |
| 13 | Tax expense of discontinued operations | 0 | 0 |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | 0 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 105000000 | 330000000 |
| 16 | Total profit (loss) for period | 4145000000 | 15051000000 |
| 17 | Other comprehensive income net of taxes | -30000000 | -63000000 |
| 18 | Total Comprehensive Income for the period | 4115000000 | 14988000000 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 3896000000 | 14459000000 | |
| Total profit or loss, attributable to non-controlling interests | 249000000 | 592000000 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 3871000000 | 14409000000 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 244000000 | 579000000 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 719000000 | 719000000 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 81326000000 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 27.1 | 100.56 | |
| Diluted earnings (loss) per share from continuing operations | 27.1 | 100.56 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 27.1 | 100.56 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 27.1 | 100.56 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Statement of Asset and Liabilities |
|||
|---|---|---|---|
| Particulars | Year ended (dd-mm-yyyy) | ||
| Date of start of reporting period | 01-Apr-2024 | ||
| Date of end of reporting period | 31-Mar-2025 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 98157000000 | ||
| Capital work-in-progress | 7710000000 | ||
| Investment property | 28000000 | ||
| Goodwill | 10305000000 | ||
| Other intangible assets | 1392000000 | ||
| Intangible assets under development | 1500000000 | ||
| Biological assets other than bearer plants | 0 | ||
| Investments accounted for using equity method | 2241000000 | ||
| Non-current financial assets | |||
| Non-current investments | 8304000000 | ||
| Trade receivables, non-current | 0 | ||
| Loans, non-current | 272000000 | ||
| Other non-current financial assets | 2126000000 | ||
| Total non-current financial assets | 10702000000 | ||
| Deferred tax assets (net) | 131000000 | ||
| Other non-current assets | 4119000000 | ||
| Total non-current assets | 136285000000 | ||
| 2 | Current assets | ||
| Inventories | 4808000000 | ||
| Current financial asset | |||
| Current investments | 14323000000 | ||
| Trade receivables, current | 30161000000 | ||
| Cash and cash equivalents | 5781000000 | ||
| Bank balance other than cash and cash equivalents | 7821000000 | ||
| Loans, current | 51000000 | ||
| Other current financial assets | 1822000000 | ||
| Total current financial assets | 59959000000 | ||
| Current tax assets (net) | 0 | ||
| Other current assets | 5522000000 | ||
| Total current assets | 70289000000 | ||
| 3 | Non-current assets classified as held for sale | 0 | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0 | |
| Total assets | 206574000000 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 719000000 | ||
| Other equity | 81404000000 | ||
| Total equity attributable to owners of parent | 82123000000 | ||
| Non controlling interest | 4406000000 | ||
| Total equity | 86529000000 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 44170000000 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0 | ||
| Total Trade payable | 0 | ||
| Other non-current financial liabilities | 24452000000 | ||
| Total non-current financial liabilities | 68622000000 | ||
| Provisions, non-current | 886000000 | ||
| Deferred tax liabilities (net) | 4580000000 | ||
| Deferred government grants, Non-current | 0 | ||
| Other non-current liabilities | 168000000 | ||
| Total non-current liabilities | 74256000000 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 8582000000 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 808000000 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 21597000000 | ||
| Total Trade payable | 22405000000 | ||
| Other current financial liabilities | 10350000000 | ||
| Total current financial liabilities | 41337000000 | ||
| Other current liabilities | 2643000000 | ||
| Provisions, current | 1793000000 | ||
| Current tax liabilities (Net) | 16000000 | ||
| Deferred government grants, Current | 0 | ||
| Total current liabilities | 45789000000 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0 | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0 | |
| Total liabilities | 120045000000 | ||
| Total equity and liabilites | 206574000000 | ||
| Disclosure of notes on assets and liabilities | |||
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 | |||||
| Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 | |||||
| Whether accounts are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Healthcare services | 28431000000 | 112201000000 | ||||
| 2 | Retail health & diagnostics | 3940000000 | 15535000000 | ||||
| 3 | Digital health & pharmacy distribution | 23763000000 | 90930000000 | ||||
| 4 | Others | 12000000 | 48000000 | ||||
| Total Segment Revenue | 56146000000 | 218714000000 | |||||
| Less: Inter segment revenue | 224000000 | 224000000 | |||||
| Revenue from operations | 55922000000 | 217940000000 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Healthcare services | 5264000000 | 21295000000 | ||||
| 2 | Retail health & diagnostics | 118000000 | 300000000 | ||||
| 3 | Digital health & pharmacy distribution | 230000000 | 1127000000 | ||||
| 4 | Others | -25000000 | -79000000 | ||||
| Total Profit before tax | 5587000000 | 22643000000 | |||||
| i. Finance cost | 1148000000 | 1148000000 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | -611000000 | -611000000 | |||||
| Profit before tax | 5050000000 | 20061000000 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Healthcare services | 127404000000 | 127404000000 | ||||
| 2 | Retail health & diagnostics | 13277000000 | 13277000000 | ||||
| 3 | Digital health & pharmacy distribution | 29629000000 | 29629000000 | ||||
| 4 | Others | 280000000 | 280000000 | ||||
| Total Segment Asset | 170590000000 | 170590000000 | |||||
| Un-allocable Assets | 35984000000 | 35984000000 | |||||
| Net Segment Asset | 206574000000 | 206574000000 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Healthcare services | 41108000000 | 41108000000 | ||||
| 2 | Retail health & diagnostics | 11005000000 | 11005000000 | ||||
| 3 | Digital health & pharmacy distribution | 10206000000 | 10206000000 | ||||
| 4 | Others | 179000000 | 179000000 | ||||
| Total Segment Liabilities | 62498000000 | 62498000000 | |||||
| Un-allocable Liabilities | 57547000000 | 57547000000 | |||||
| Net Segment Liabilities | 120045000000 | 120045000000 | |||||
| Disclosure of notes on segments | |||||||
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 |
| B | Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement gains / (losses) on defined benefit plan | -36000000 | -84000000 |
| 2 | Equity instruments through other comprehensive income | -2000000 | -2000000 |
| Total Amount of items that will not be reclassified to profit and loss | -38000000 | -86000000 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | -9000000 | -17000000 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Exchange differences in translating the financial statements of foreign operations | -1000000 | 6000000 |
| Total Amount of items that will be reclassified to profit and loss | -1000000 | 6000000 | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | 0 |
| 5 | Total Other comprehensive income | -30000000 | -63000000 |
Cash flow statement, indirect |
||||||
|---|---|---|---|---|---|---|
| Particulars | Year ended (dd-mm-yyyy) | |||||
| A | Date of start of reporting period | 01-Apr-2024 | ||||
| B | Date of end of reporting period | 31-Mar-2025 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Consolidated | ||||
| Part I | Blue color marked fields are non-mandatory. | |||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 20061000000 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 4585000000 | |||||
| Adjustments for decrease (increase) in inventories | -210000000 | |||||
| Adjustments for decrease (increase) in trade receivables, current | -5642000000 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0 | |||||
| Adjustments for decrease (increase) in other current assets | 0 | |||||
| Adjustments for decrease (increase) in other non-current assets | -145000000 | |||||
| Adjustments for other financial assets, non-current | 52000000 | |||||
| Adjustments for other financial assets, current | 0 | |||||
| Adjustments for other bank balances | 0 | |||||
| Adjustments for increase (decrease) in trade payables, current | -1280000000 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0 | |||||
| Adjustments for increase (decrease) in other current liabilities | 0 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 264000000 | |||||
| Adjustments for depreciation and amortisation expense | 7575000000 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 20000000 | |||||
| Adjustments for provisions, current | 460000000 | |||||
| Adjustments for provisions, non-current | 0 | |||||
| Adjustments for other financial liabilities, current | 0 | |||||
| Adjustments for other financial liabilities, non-current | 438000000 | |||||
| Adjustments for unrealised foreign exchange losses gains | 1000000 | |||||
| Adjustments for dividend income | 7000000 | |||||
| Adjustments for interest income | 924000000 | |||||
| Adjustments for share-based payments | 1127000000 | |||||
| Adjustments for fair value losses (gains) | -634000000 | |||||
| Adjustments for undistributed profits of associates | 0 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | -69000000 | |||||
| Other adjustments to reconcile profit (loss) | 0 | |||||
| Other adjustments for non-cash items | 629000000 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Total adjustments for reconcile profit (loss) | 6240000000 | |||||
| Net cash flows from (used in) operations | 26301000000 | |||||
| Dividends received | 0 | |||||
| Interest paid | 0 | |||||
| Interest received | 0 | |||||
| Income taxes paid (refund) | 4937000000 | |||||
| Other inflows (outflows) of cash | 0 | |||||
| Net cash flows from (used in) operating activities | 21364000000 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 18151000000 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 32176000000 | |||||
| Other cash receipts from sales of interests in joint ventures | 0 | |||||
| Other cash payments to acquire interests in joint ventures | 0 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Proceeds from sales of property, plant and equipment | 149000000 | |||||
| Purchase of property, plant and equipment | 17127000000 | |||||
| Proceeds from sales of investment property | 0 | |||||
| Purchase of investment property | 0 | |||||
| Proceeds from sales of intangible assets | 0 | |||||
| Purchase of intangible assets | 0 | |||||
| Proceeds from sales of intangible assets under development | 0 | |||||
| Purchase of intangible assets under development | 0 | |||||
| Proceeds from sales of goodwill | 0 | |||||
| Purchase of goodwill | 0 | |||||
| Proceeds from biological assets other than bearer plants | 0 | |||||
| Purchase of biological assets other than bearer plants | 0 | |||||
| Proceeds from government grants | 0 | |||||
| Proceeds from sales of other long-term assets | 0 | |||||
| Purchase of other long-term assets | 0 | |||||
| Cash advances and loans made to other parties | 291000000 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 84000000 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0 | |||||
| Dividends received | 98000000 | |||||
| Interest received | 844000000 | |||||
| Income taxes paid (refund) | 0 | |||||
| Other inflows (outflows) of cash | -3538000000 | |||||
| Net cash flows from (used in) investing activities | -33806000000 | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0 | |||||
| Payments from changes in ownership interests in subsidiaries | 24000000 | |||||
| Proceeds from issuing shares | 459000000 | |||||
| Proceeds from issuing other equity instruments | 0 | |||||
| Payments to acquire or redeem entity's shares | 0 | |||||
| Payments of other equity instruments | 0 | |||||
| Proceeds from exercise of stock options | 0 | |||||
| Proceeds from issuing debentures notes bonds etc | 0 | |||||
| Proceeds from borrowings | 25511000000 | |||||
| Repayments of borrowings | 4422000000 | |||||
| Payments of lease liabilities | 2563000000 | |||||
| Dividends paid | 2784000000 | |||||
| Interest paid | 3019000000 | |||||
| Income taxes paid (refund) | 0 | |||||
| Other inflows (outflows) of cash | 10000000 | |||||
| Net cash flows from (used in) financing activities | 13168000000 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 726000000 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0 | |||||
| Net increase (decrease) in cash and cash equivalents | 726000000 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 5055000000 | |||||
| Cash and cash equivalents cash flow statement at end of period | 5781000000 | |||||
Details of Impact of Audit Qualification |
|
|---|---|
| Whether results are audited or unaudited | Audited |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Deloitte Haskins & Sells LLP | Yes | 31-Jul-2027 | ||
|---|---|---|---|---|---|